Results 11 to 20 of about 21,434 (231)

Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease

Journal of Pharmacological Sciences, 2015
The therapeutic response rates of patients to donepezil vary from 20% to 60%, one of the reasons is their genetic differences in donepezil-metabolizing enzymes, which directly influence liver metabolism. However, the mechanism of donepezil metabolism and
Jin Lu, Lili Wan, Yuan Zhong, Qi Yu, Yonglong Han, Pengguo Chen, Beiyun Wang, Wei Li, Ya Miao, Cheng Guo   +9 more
doaj   +2 more sources

Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect

Journal of Pharmacological Sciences, 2019
Oxaliplatin induces severe peripheral neuropathy. The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models.
Takehiro Kawashiri, Shiori Shimizu, Nao Shigematsu, Daisuke Kobayashi, Takao Shimazoe   +4 more
doaj   +2 more sources

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients

Clinical Interventions in Aging, 2018
Nan Zhang,1,2 Marc L Gordon3,4 1Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Tianjin, People’s Republic of China; 2Department of Neurology and Neurosurgery, Tianjin Medical University ...
Zhang N, Gordon ML
doaj   +1 more source

Donepezil Adherence, Persistence and Time to First Discontinuation in a Three-Year Follow-Up of Older People [PDF]

Dementia and Geriatric Cognitive Disorders Extra, 2015
Background: Donepezil is indicated for the management of mild to moderate dementia, particularly in Alzheimer's disease. Several studies have described low adherence rates with donepezil.
Henry C. Ndukwe, Prasad S. Nishtala
doaj   +2 more sources

Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers

Drug Design, Development and Therapy, 2015
Yo Han Kim,1 Hee Youn Choi,1 Hyeong-Seok Lim,1 Shi Hyang Lee,1 Hae Sun Jeon,1 Donghyun Hong,2 Seong Su Kim,2 Young Kweon Choi,2 Kyun-Seop Bae1 1Department of Clinical Pharmacology and Therapeutics, College of Medicine, University of Ulsan, Asan Medical ...
Kim YH, Choi HY, Lim HS, Lee SH, Jeon HS, Hong D, Kim SS, Choi YK, Bae KS   +8 more
doaj   +1 more source

Synthesis and Evaluation of Novel Cinnamic Acid Hybrids With Antiacetylcholinesterase, Antioxidant, and Anti-Inflammatory Properties. [PDF]

ChemMedChem
In this work, we identified two novel pleiotropic sinapic acid derivatives with excellent anti‐acetylcholinesterase, antioxidant, and anti‐inflammatory properties. Alzheimer's disease, one of the most widespread neurodegenerative disorders, is known for its multifactorial nature that makes it challenging to treat.
Sdougkou K, Rekka E, Papagiannopoulou D.
europepmc   +2 more sources

Age-Dependent Remodeling of the Sciatic Nerve Proteome in 5xFAD Mice Can Be Attenuated by Exercise or Donepezil Treatment to Maintain Neuromuscular Function. [PDF]

Aging Cell
Sciatic nerve proteome remodeling, particularly of mitochondrial‐centric pathways, occurs at 4 months of age in 5xFAD mice, coinciding with onset of neuromuscular dysfunction. Exercise or the acetylcholinesterase inhibitor donepezil, begun prior to onset, delays these phenotypes, suggesting early peripheral phenotypes of Alzheimer's Disease may have ...
Brisendine MH, Nieves-Esparcia DQ, Willoughby OS, Brown B, Brown JR, Braxton DS, Henry SN, McCoin CS, Thyfault JP, Morris JK, Poelzing S, Grange RW, Jarome TJ, Najt CP, Drake JC.   +14 more
europepmc   +2 more sources

Donepezil and Memantine for moderate-to-severe Alzheimer's disease [PDF]

, 2012
Background Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease ...
O'Brien, John, Roy Jones (3539210), Juszczak, E, R. Brown (3682735), Gray, R, Richard Gray (2619970), Ballard, C, Burns, Alistair; id_orcid, Adams, Jessica, Knapp, M, J. Adams (7579901), Knapp, Martin, Robert Hills (3685870), Baldwin, A, P. Passmore (7608800), Dening, Tom, Griffin, M, S. Banerjee (1503751), B. Sheehan (7608761), Jones, Roy, T. Dening (7608776), Craig Ritchie (3531092), Sheehan, Bart, McShane, R, Mary Griffin (3203010), Bentham, Peter, O'Brien, John, Bart Sheehan (3836236), McShane, Rupert, Brown, R, Clive Holmes (237359), Dening, T, Hughes, Alan, Robin Jacoby (89610), Jones, R., Holmes, C, Clive Ballard (89605), Jacoby, Robin, Phillips, Patrick, Alan Hughes (178653), Sube Banerjee (4464202), D. Findlay (7608779), McKeith, I, Martin Knapp (146158), Ritchie, C. W., A. Baldwin (7608767), Ritchie, Craig, P. Phillips (5239541), Barber, R, C. Katona (6059216), David Findlay (46833), Banerjee, S, P. Bentham (7589273), Juszczak, Ed, Peter Bentham (16155026), Ashley Baldwin (14422653), Cornelius Katona (15210), Brown, Richard, J. Lindesay (7635890), McKeith, Ian, Barber, Robert, Brown, Richard; id_orcid, E. Juszczak (7589267), Burns, A, Banerjee, Sube, Macharouthu, Ajay, Edmund Juszczak (89612), Passmore, P, Jones, R, James Lindesay (7582160), Gray, Richard, Phillips, P, R. Jacoby (7589288), J. O'Brien (7608797), Robert Barber (337950), Phillips, P., A. Burns (842688), Tom Dening (3097692), R. Howard (1274091), Juszczak, Edmund, Ian McKeith (369422), Patrick Phillips (1420741), C. Holmes (7589285), Peter Passmore (254593), M. Griffin (3933326), Macharouthu, A, M. Knapp (2534038), Rupert McShane (89609), C. Ballard (7608770), Passmore, Peter, Johnson, T, R. l. Barber (7635893), Robert Howard (190740), Hills, Robert Kerrin, Findlay, David, Jacoby, R, Johnson, T., Hughes, A., Barber, R., Howard, Robert, Jessica Adams (2640001), Jones, Roy W., O'Brien, J. T., R. McShane (7608791), Howard, R, Holmes, Clive, Katona, C, Lindesay, J, I. McKeith (7608788), Ritchie, C, Adams, J., A. Macharouthu (7608794), T. Johnson (7602368), Johnson, Tony, McKeith, I. G., A. Hughes (7190519), Jones, Rob, Caroline Onions (16155023), Katona, C. L. E., R. Hills (7635896), John O'Brien (377563), Hills, Robert, Hughes, A, Lindesay, James, Hills, R, Rob Jones (3023226), Tony Johnson (1947625), Onions, Caroline, Griffin, Mary, C. Ritchie (7608806), Onions, C, Richard Brown (130157), Katona, Cornelius, Baldwin, Ashley, Sheehan, B, Adams, J, Burns, Alistair, Burns, Alistair S., Griffin, M., R. Jones (3979994), Ballard, Clive, C. Onions (7608764), Alistair Burns (3580904), Findlay, D, O'Brien, J, Bentham, P, R. Gray (7608782), Ajay Macharouthu (6553472)   +147 more
core   +1 more source

Donepezil Potentiates Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells

Journal of Pharmacological Sciences, 2007
Donepezil is a potent and selective acetylcholinesterase inhibitor developed for the treatment of Alzheimer’s disease. To elucidate whether donepezil causes neuronal differentiation, we examined its effect on nerve growth factor (NGF)-induced neurite ...
Toru Oda, Toshiaki Kume, Hiroshi Katsuki, Tetsuhiro Niidome, Hachiro Sugimoto, Akinori Akaike   +5 more
doaj   +1 more source

Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model

Biomolecules, 2020
Donepezil is an acetylcholinesterase inhibitor commonly used to treat mild to moderate Alzheimer’s disease. Its use has been associated with increased bone mass in humans and animals.
Faez Saleh Al-Hamed, Ola M. Maria, Jeff Phan, Ahmed Al Subaie, Qiman Gao, Alaa Mansour, Lina Abu Nada, Imane Boukhatem, Osama A. Elkashty, Simon D. Tran, Marie Lordkipanidzé, Zahi Badran, Faleh Tamimi   +12 more
doaj   +1 more source